virological data: both in patients in the experimental dualregimen arm and in the triple-drug arm, seminal plasma HIV RNA was undetectable. These data support the seminal virological effectiveness of the once-daily maraviroc plus lopinavir/ritonavir association and confirm, in general terms, the results of previous data on protease inhibitor-based dual regimens in the male genital tract.
In this setting, tropism can be determined from cellular HIV-1 DNA. 3 However, it remains unclear how potent cART without CCR5 antagonists might influence the evolution of HIV-1 DNA tropism.
The objective of this study was to describe the evolution of HIV-1 DNA tropism in patients receiving a fusion inhibitor-based regimen in different clinical settings.
Patients from two randomized clinical trials with a fusion inhibitor (enfuvirtide) arm were analysed: (i) the Agence Nationale de Recherches sur le SIDA et les hé patites virales (ANRS) 130 APOLLO study that enrolled severely immunocompromised cART-naive patients; 4, 5 and (ii) the INNOVE study that enrolled cART-experienced patients with virological failure. 6 Patients received enfuvirtide in addition to cART for 6 months in the APOLLO study and 3 months in the INNOVE study. In the APOLLO and INNOVE studies, 100 and 14 patients were included in the enfuvirtide arm, respectively.
HIV-1 DNA tropism was assessed at baseline and at week 24 of cART by V3 loop sequencing using the ANRS protocol (www.hivfrenchresistance.org). HIV-1 tropism was interpreted using the Geno2Pheno algorithm (http://www.geno2pheno.org) with a false positive rate of 10%.
At baseline, among all patients enrolled in both studies, the proportion harbouring X4 viruses in peripheral blood mononuclear cells (PBMCs) was 56/121 (46%) and 10/29 (34%) in the APOLLO and INNOVE studies, respectively. Overall, tropism evolution in HIV-1 DNA was observed in 29 cases (Table 1) . HIV-1 DNA tropism change from R5 at baseline to X4 at week 24 in the enfuvirtide arms was observed in 9/48 (19%) patients in the APOLLO study and in 4/13 (31%) patients in the INNOVE study (Table 1) . Combining the APOLLO and INNOVE data, a higher frequency of HIV-1 DNA tropism change from R5 at baseline to X4 at week 24 was observed in the enfuvirtide arms than in the control arms: 13/62 (21%) versus 4/77 (5%) (P ¼ 0.0077).
Among the 13 patients displaying a tropism change from R5 at baseline to X4 at week 24 in PBMCs in the enfuvirtide arms, 10 were infected with HIV-1 subtype B. Six out of these 13 (46%) patients exhibited baseline false positive rate values between 10% and 20%, but at week 24 all false positive rate values were very low, below 5.3%. Among these 13 samples, the 11/25 rule would have predicted X4 tropism at baseline in 2 samples, both exhibiting a limit false positive rate value (11.5%).
Twelve out of the 13 patients with an R5 to X4 switch in HIV-1 DNA between baseline and week 24 had virological success at week 24. Regarding immunological response, the median change in the CD4 cell count between baseline and week 24, in patients exhibiting a tropism switch from R5 to X4 in PBMCs, was +189 cells/mm 3 (IQR ¼ +161 to +248), compared with +167 (IQR ¼+105 to +205) in patients with stable R5 tropism.
In patients with different immunovirological characteristics from two randomized clinical trials assessing enfuvirtide intensification, either as part of a first-line cART or as part of a salvage therapy for virological failure, we observed frequent and rapid changes in HIV-1 DNA tropism from R5 to X4 in the enfuvirtide arms in spite of virological success and the absence of CCR5 antagonist treatment.
The findings presented herein are not in keeping with those of the Phase 3 clinical trials of enfuvirtide, which showed common HIV-1 tropism change from X4 to R5 in the enfuvirtide arm. 7 However, in that study, tropism testing was performed in plasma viruses and only in patients with virological failure, a different setting that could explain the differences.
Previous studies in cART-treated patients, without entry inhibitors, showed that HIV-1 DNA tropism was unchanged in ≥90% of cases after 2-6 years of cART. Among those with changes, switches from X4 to R5 or R5 to X4 were reported in similar proportions. 8, 9 In the present study, no factor associated with an increased risk of switch from R5 to X4 could be evidenced, as previously described for a low CD4 nadir. 1 In addition, in the APOLLO study, the intensification of initial cART with enfuvirtide did not improve immunological reconstitution in spite of a higher rate of virological response. 4 So, one can speculate that the R5 to X4 tropism switch might have a deleterious effect on immune reconstitution.
European guidelines on tropism testing in the clinical management of HIV-1 recommend increasing the false positive rate to up to 20% in case of tropism determination from PBMCs. 10 Thus, the proportion of HIV-1 DNA change due to a misclassification of baseline HIV-1 DNA tropism might have been overestimated in our study when using the 10% false positive rate threshold. Indeed, when taking 20% as the false positive rate threshold, a switch from R5 to X4 in PBMCs between baseline and week 24 was observed in 11% of the patients, compared with 21% with a 10% false positive rate threshold.
Thus, when a cART switch to a CCR5 inhibitor-based regimen is considered in virologically suppressed patients, a higher false positive rate threshold might be relevant to improve tropism prediction in patients on a regimen containing enfuvirtide (or another fusion inhibitor). The molecular mechanisms involved in tropism change whilst taking a fusion inhibitor are as yet unclear and further studies are warranted to better understand these underlying mechanisms. 
